Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Amyotrophic Lateral Sclerosis(ALS) Clear all
Not yet recruiting Not applicable Interventional

Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro

NCT07209943
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury, SCI - Spinal Cord Injury, Stroke
Interventions
Cognixion + Apple Vision Pro
Device
Lead sponsor
Cognixion
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 6, 2026, 2:02 PM EDT
Not listed No phase listed Observational

A Study to Evaluate the Performance of a Diagnostic Test in ALS

NCT02759913
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Lumbar puncture
Procedure
Lead sponsor
Iron Horse Diagnostics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 6, 2026, 2:02 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 6, 2026, 2:02 PM EDT
Completed No phase listed Observational

Speech Analysis in ALS Patients

NCT03868345
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
Interventions
Not listed
Lead sponsor
Barrow Neurological Institute
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 6, 2026, 2:02 PM EDT
Completed No phase listed Observational

PRISM Registry: Pseudobulbar Affect Registry Series

NCT01366027
View directory record Official record
Conditions
Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease, Stroke, Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aliso Viejo, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial Nuedexta in Subjects With ALS

NCT01806857
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Nuedexta, Matching Placebo
Drug
Lead sponsor
Center for Neurologic Study, La Jolla, California,
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 6, 2026, 2:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ASSESS ALL ALS Study

NCT06578195
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 6, 2026, 2:02 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

NCT06100276
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMT-162
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 6, 2026, 2:02 PM EDT
Completed No phase listed Observational

Online Self-Compassion Course for pALS (Compassion pALS)

NCT05202743
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Observational for ALS patients
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 6, 2026, 2:02 PM EDT
Completed No phase listed Observational

Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis

NCT00339976
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

NCT02496767
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tirasemtiv, Placebo tablets
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 6, 2026, 2:02 PM EDT
Recruiting Early Phase 1 Interventional

Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

NCT07224269
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities
Interventions
Terazosine, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Exploratory Evaluation of [11C]MPC6827

NCT04575727
View directory record Official record
Conditions
Neurodegenerative Diseases, Alzheimer Disease, Amyotrophic Lateral Sclerosis
Interventions
[11C]MPC6827
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 6, 2026, 2:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Electrical Impedance Myography (EIM) in ALS

NCT02011204
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Marie-Tooth Disease, Multiple Sclerosis
Interventions
Electrical impedance myography (EIM)
Device
Lead sponsor
Skulpt, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Phoenix, Arizona • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

NCT05163886
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
LAM-002A, Placebo
Drug · Other
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

NCT01041222
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
ISIS 333611
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Charlestown, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Not applicable Interventional

Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and Caregivers

NCT04719403
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
HealthPAL
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT02460679
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
EPI-589
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
21 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 6, 2026, 2:02 PM EDT
Recruiting No phase listed Observational

Analysis of Human ALS Tissues and Registry of ALS Patients

NCT05067179
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease

NCT03645031
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Neuromuscular Diseases
Interventions
Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 6, 2026, 2:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Familial and Sporadic ALS

NCT00821132
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease, Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS), Sporadic ALS (SALS)
Interventions
Genetic study of ALS families
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
13,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 6, 2026, 2:02 PM EDT
Recruiting Not applicable Interventional

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

NCT07521930
View directory record Official record
Conditions
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Muscular Disorders, Atrophic, Brain Stem Stroke, Spinal Cord Injuries (SCI), Muscular Dystrophies, Muscular Atrophy, Progressive, Pontine Hemorrhage, Pontine Infarction
Interventions
INTENT Neural Interface System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 6, 2026, 2:02 PM EDT
Recruiting Not applicable Interventional

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

NCT07543367
View directory record Official record
Conditions
Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis, ALS
Interventions
Stentrode
Device
Lead sponsor
Synchron, Inc.
Industry
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Jacksonville, Florida • Buffalo, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 6, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00748501
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SB-509
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
La Jolla, California • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 6, 2026, 2:02 PM EDT